Latest News

Biopharma Co. Planning BLA for DMD Drug

August 8, 2022 ( Newswire) Sarepta Therapeutics Inc. recently announced that it intends to submit a BLA to the U.S. FDA for its SRP-9001, a gene therapy to treat Duchenne muscular dystrophy. Equity research firm BTIG LLC advised in a research update that SRP-9001 seems to have met the necessary criteria for receiving accelerated approval and it expects an AdCom will be established shortly. BTIG stated that it rates Sarepta Therapeutics as a “Buy” and has a $125 price target for the company’s shares.

In a July 29 research note, Biotechnology Technology Equity Research LLC (BTIG LLC) Analyst Yun Zhong, Ph.D. advised that Sarepta Therapeutics Inc. (SRPT:NASDAQ) recently announced that this autumn it plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its Duchenne muscular dystrophy (DMD) drug SRP-9001. The firm expects that the BLA for SRP-9001 will fall under the accelerated approval pathway reflecting the strength of Sarepta’s research and clinical program data and the flexibility that the FDA has afforded to new therapeutics targeting largely unmet medical needs.

BTIG noted that it is likely that an advisory committee (AdCom) will be convened by the FDA to evaluate the information presented in the BLA. The analyst mentioned that earlier in July Sarepta released full one-year data from three studies in which patients treated with SRP-9001 demonstrated statistically significant results across multiple key endpoints.

BTIG advised that as the company previously submitted the same dataset to the FDA it believes that the decision to move forward with the BLA filing may be due to positive feedback received from the agency.

The analyst explained that the threshold for accelerated approval is predicated upon either the use of a “reasonably likely to predict clinical benefit” surrogate endpoint or an intermediate clinical endpoint that can be “measured earlier than irreversible morbidity or mortality.”

BTIG indicated that though it is uncertain, there is a good chance that the FDA may decide to grant accelerated approval for SRP-9001. BTIG said that potentially SRP-9001’s accelerated approval might be based on microdystrophin expression as a surrogate endpoint. The research firm stated that across all trial age groups SRP-9001 has shown “robust and consistent microdystrophin expression levels.”

The analyst commented that if the proposed filing in the fall goes according to the schedule outlined by the company, the FDA may rule on and accept the priority review BLA submission prior to the end of this year with The Prescription Drug User Fee Act (PDUFA) data available during mid-2023.

BTIG said that positive data from Sarepta’s ongoing Phase 3 trial forms the basis for its projections of achieving full approval for SRP-9001 in 2024, with Sarepta starting booking revenue in the U.S. in the same year.

The analyst from BTIG commented, “We believe an accelerated approval for SRP-9001 would be an important win for Sarepta given the close competition with Pfizer Inc. (PFE:NYSE) (Not Rated by BTIG) and we have always believed that SRP-9001 is a superior program between the two.”

BTIG cautioned that it is possible that definitive proof of correlation between microdystorphin and clinical benefit may be insufficient. However, the firm pointed out that “Sarepta has successfully received three FDA approvals for exon-skipping products using truncated dystrophin as a surrogate endpoint.”

The analyst noted that even though Sarepta has three separate FDA-approved products in the market the company’s valuation is also dependent on the development potential of its clinical pipeline.

Sarepta Therapeutics Inc. is a biotechnology company based in Cambridge, Mass. that is engaged in developing and marketing precision medicines for complex and rare genetic diseases. Sarepta is highly focused on seeking new treatments for both Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs). The firm presently has three FDA-approved products in the market along with over 40 active development programs in its RNA Technologies, Gene Therapy, and Gene Editing pipelines.

Biotechnology Technology Equity Research advised that it has a “Buy” rating and a $125.00 price target for Sarepta Therapeutics Inc. The firm indicated that it arrived at that price by taking an average of three different valuation methods including discounted earnings, discounted cash flow, and clinical net present value.

Sarepta Therapeutics’ shares trade on the Nasdaq Exchange under the symbol “SRPT” and last closed for trading at $101.45 on Thursday, August 4, 2022. The company has approximately 87.5 million shares outstanding and a market cap of about $8.41 billion. It is currently trading at $49.92 per share.


1) Stephen Hytha wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.

3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures for BTIG Research., Sarepta Therapeutics Inc., July 29, 2022

Analyst Certification: I, Yun Zhong, hereby certify that the views about the companies and securities discussed in this report are accurately expressed and that I have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report.

Company-Specific Regulatory Disclosures: BTIG LLC expects to receive or intends to seek compensation for investment banking services in the next 3 months from: Sarepta Therapeutics, Inc. (SRPT) BTIG LLC expects to receive or intends to seek compensation for investment banking services in the next 3 months from: Biogen, Inc. (BIIB)

General Disclosures: Research reports produced by BTIG LLC (“BTIG”) are published for and intended to be distributed solely to BTIG institutional and corporate clients. Recipients of BTIG reports will not be considered clients of BTIG solely because they may have received such BTIG report. To the extent recipient accesses BTIG research, whether on a BTIG research website or through a third-party platform, BTIG is able to search, filter, download and review information on the readership of BTIG’s research, including the specific research consumed and the name, company name, email address and, in certain circumstances, the location of the individual who accessed the research (the “Readership Information”). Recipient consents to BTIG’s receipt of the Readership Information, including receipt of that information from a third party.

The research analyst(s) responsible for the preparation of this report receives compensation based upon a variety of factors, including the quality and accuracy of research, internal/client feedback, and overall Firm revenues. BTIG reports are based on public information and BTIG considers the same to be reliable, comprehensive information, but makes no representation or warranty that the reports are accurate or complete. BTIG opinions and information provided in this report are as of the date of the report and may change without notice. An issuer may be classified as “Under Review” or “Research Restricted”. In these cases, investors should consider any previous investment recommendation and/or rating to a subject company/issuer to no longer be current and should not be relied upon nor considered a solicitation.

This research report is not an offer to buy or sell or solicitation of an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal. This research report was not drafted specifically for any particular individual or entity and is not a personal recommendation to participate in any particular trading strategy or transaction. Any recipient of this research report should obtain independent advice specific to their personal circumstances before undertaking any investment activity and must make their own independent evaluation of any securities or financial instruments.

Facts, views or opinions presented in this report have not been reviewed by, and may not reflect information known to, employees or other professionals in the “BTIG Group” (BTIG Group includes, but is not limited to, BTIG and its parents, subsidiaries and/ or affiliates). BTIG Group employees, including Sales Representatives and Traders, may provide oral or written commentary or advice that may be inconsistent with the opinions and/or views expressed in this research report. BTIG Group employees and/or its affiliates not involved in the preparation of this research report may have investments in securities or derivatives of securities of companies mentioned in this report that are inconsistent with the views discussed in this report.

Investors in securities products bear certain risks in conjunction with those investments. The value of, and income from, any investments may vary because of changes in interest rates or foreign exchange rates, securities prices or market indexes, operational or financial conditions of companies or other factors within or beyond the companies’ control. Recipient of the research reports should be aware that investments in securities may pose significant risks due to the inherent uncertainty associated with relying on forecasts of various factors that can affect the earnings, cash flow and overall valuation of a company.

Any investment in securities should be undertaken only upon consideration of issues relating to the recipient’s overall investment portfolio and objectives (such as diversification by asset class, industry or company) as well as time horizon and liquidity needs. Further, past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. There may be time limitations on the exercise of options or other rights in any securities transactions. Investing in foreign markets and securities, including ADRs, is subject to additional risks such as currency fluctuation, limited information, political instability, economic risk, and the potential for illiquid markets. Investing in emerging markets may accentuate these risks. Non-U.S. reporting issuers of foreign securities, however, may not make regular or complete public disclosure relating to their financial condition or the securities that they issue.

The trademarks and service marks contained herein are the property of their respective owners. Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability of any damages of any kind relating to such data. The report or any portion hereof may not be reprinted, sold or redistributed without the written consent of BTIG. This report is intended only for use by the recipient. The recipient acknowledges that all research and analysis in this report are the property of BTIG and agrees to limit the use of all publications received from BTIG within his, or her or its, own company or organization. No rights are given for passing on, transmitting, re transmitting or reselling the information provided.

More Info:

This news is published on the Newswire – a global digital news source for investors and business leaders

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire and

Global investors must adhere to regulations of each country. Please read privacy policy: – investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Buy a biotech guest post on

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *